

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**Segment wise Revenue, Results and Capital Employed,
under Clause 41 of the Listing Agreement**

(Rs. lakhs)

Unaudited			Unaudited		Audited
3 months ended	3 months ended		9 months ended	9 months ended	Year ended
30.09.2007	30.09.2006		30.09.2007	30.09.2006	31.12.2006
40359	36914	1. Segment Revenue:			
3287	4006	a) Pharmaceuticals	118108	110922	141602
43646	40920	b) Other Businesses	9899	15080	18134
-	-	Total Segment Revenue	128007	126002	159736
43646	40920	Less: Inter Segment Revenue	-	-	-
		Net Sales / Income from Operations	128007	126002	159736
		2. Segment Results (Profit before Interest and Tax):			
15105	13219	a) Pharmaceuticals	44062	39868	49211
503	954	b) Other Businesses	1865	3004	3848
15608	14173	Total Segment Results	45927	42872	53059
		Add/(Less):			
1376	926	(i) Interest Income (net)	3441	2419	3426
(752)	(748)	(ii) Un-allocable Expenditure	(2422)	(1854)	(2605)
441	605	(iii) Un-allocable Income	1565	1435	1715
16673	14956	Total Profit Before Tax and Exceptional Items	48511	44872	55595
		3. Capital Employed (Segment Assets less Segment Liabilities):			
19113	16725	a) Pharmaceuticals	19113	16725	15849
1843	5812	b) Other Businesses	1843	5812	6040
142721	120096	c) Unallocated	142721	120096	97583
163677	142633	Total	163677	142633	119472

Notes:

1 Refer Notes 1 and 3 of the aforesaid unaudited financial results for the quarter and nine months ended 30th September, 2007

2 (i) The Company is organised into two main business segments, namely:

- Pharmaceuticals - comprising of bulk drugs and formulations

- Others - primarily comprising of fine chemicals, diagnostics, laboratory equipment and exports mainly relating to pharmaceuticals.

Animal Health business formed part of the Company's Other Businesses segment in the previous year.

Segments have been identified and reported taking into account, the nature of products and services, the differing risks and returns, the organisation structure, and the internal financial reporting systems.

(ii) Segment Revenue in each of the above domestic business segments primarily includes sales (net of excise duty), processing charges, consignment sales commission, clinical research and data management and export incentives in the respective segments.

(iii) Segment Revenue, Results, Assets and Liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.